We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Elevated Levels of Defective Mitochondrial DNA Predict Likelihood of Reproductive Success

By LabMedica International staff writers
Posted on 14 Oct 2020
A sperm biomarker has been found that may be able to supplement or replace the semen parameters that poorly predict reproductive success yet are the most prevalent diagnostic tool for male infertility.

Mitochondrial DNA is maternally inherited, and sperm mitochondrial DNA copy number (mtDNAcn) typically decreases eight-to-10 fold during spermatogenesis to ensure that it is low upon fertilization. More...
Previous studies have shown that elevated sperm mitochondrial mtDNAcn and mitochondrial DNA deletions (mtDNAdel) were associated with decreased semen quality and lowered the odds of fertilization in men seeking fertility treatment.

To confirm this association, investigators at the University of Massachusetts Amherst (USA) determined sperm mtDNAcn and mtDNAdel from 384 semen samples using triplex probe-based quantitative PCR. Probability of pregnancy within one year was compared by mitochondrial DNA.

Results revealed that men with higher sperm mtDNAcn had as much as 50% lower odds of cycle-specific pregnancy and 18% lower probability of pregnancy within 12 months. The investigators stressed that the population examined in this study consisted primarily of Caucasian men and women and thus large diverse cohorts would be necessary to confirm the associations between sperm mtDNAcn and couple pregnancy success in other races/ethnicities.

"Clinically, the diagnosis of male infertility really has not changed in decades," said senior author Dr. Richard Pilsner, associate professor of public health and health sciences at the University of Massachusetts Amherst. "In the last 10 to 20 years, there have been major advances in the understanding of the molecular and cellular functions of sperm, but the clinical diagnosis has not changed or caught up. Understanding what is causing the retention of mitochondrial copy number during spermatogenesis will help us come up with better platforms to intervene and to promote better reproductive success. The logical next step was to determine if the associations between sperm mitochondrial biomarkers and fertilization among couples seeking infertility treatment could be extended to couples from the general population,"

The mitochondrial DNA study was published in the October 6, 2020, online edition of the journal Human Reproduction.

Related Links:
University of Massachusetts Amherst


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.